MLAB — Mesa Laboratories, Inc.

Is MLAB overbought or oversold? Here is the current MarketMoodz read.

Technology · Scientific & Technical Instruments

Overbought As of November 17, 2026

Mesa Laboratories, Inc. (MLAB) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Technology name (Scientific & Technical Instruments) last closed at $134.09. The rating moved from Oversold to Overbought on November 12, 2026.

See all overbought Technology stocks →

AI analysis

Mesa Laboratories operates in a specialized, defense‑oriented segment of healthcare and laboratory instrumentation with recurring service and consumable revenue that supports steady cash flow. Near‑term catalysts include continued demand for monitoring and sterilization solutions and modest growth from product introductions or bolt‑on acquisitions. Key challenges are customer concentration, regulatory exposure, and supply‑chain or execution risks typical for small industrial/medical device firms. Given limited social‑media chatter and a cautious macro tone centered on policy signals, price moves are likely to be driven more by company fundamentals and quarterly results than broad-market headline volatility.

Key factors

  • Niche market position supplying monitoring, calibration and sterilization equipment with recurring consumables and service revenue
  • Historically stable cash flows and margin resilience driven by regulated healthcare and lab end markets
  • Defensive demand characteristics: revenue less correlated with broad cyclicality compared with discretionary tech names
  • Potential for incremental growth through product expansion and selective acquisitions in adjacent instrumentation niches
  • Limited exposure to headline-driven semiconductor/AI volatility noted in broader market themes

Risks

  • Customer concentration risk or reliance on a relatively small number of institutional buyers
  • Regulatory and reimbursement changes or tightened procurement budgets at healthcare institutions
  • Supply‑chain disruptions or component shortages affecting manufacturing or lead times
  • Small‑cap liquidity and limited analyst coverage can amplify price moves and reduce visibility
  • Management / succession risk and execution risk on any acquisition integration or new product launches
  • Macroeconomic pressure from tighter monetary policy that can slow capital equipment purchases

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MLAB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.